Anti-renin-angiotensin-system drugs and development of anemia in chronic kidney disease

Journal of Nephrology

Volumn 18, Issue 5, 2005, Pages 585-591

  Piccoli, Antonio ^a   Pastori, Giordano ^a   Pierobon, Erika ^a   Torraca, Serena ^b   Andreucci, Michele ^b   Sabbatini, Massimo ^b   Cianciaruso, Bruno ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ACE inhibitor; Anemia; Angiotensin receptor antagonist; Chronic kidney disease; Chronic renal failure; Renal anemia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; FEMALE; GENDER; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; OUTPATIENT; PATHOGENESIS; PREDICTION; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME;

ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; ERYTHROPOIESIS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 29244476852     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. National Kidney Foundation. K/DOQI Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37 (suppl 1): S182-238.
2. Isselbacher KJ, Braunwald E, Wilson J, Martin JB, Fauci AS, Kasper DL. Harrison's principle of internal medicine. New York: McGraw-Hill 2001; 2493.
3. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S; European Best Practice Guidelines Working Group. Revised European best practice guidelines (EBPG) for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (suppl 2): S1-S47.
4. Erlev AJ, Besarab A. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure. Kidney Int 1997; 51: 622-30.
5. Levin A, Thompson C, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jinkal K, Barett B, Singer J, Djurdjev O. Left ventricular mass growth in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-34.
6. Levin A. The role of anemia in the genesis of cardiac abnormalities in patients with chronic kidney disease. Nephrol Dial Transplant 2002; 17: 207-10.
7. Perazzella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis 1995; 26: 495-500.
8. Ducloux D, Saint-Hillier J, Chalopin JM. Effect of losartan on Haemoglobin concentration in renal transplant recipients: a retrospective analysis. Nephrol Dial Transplant 1997; 12: 2683-6.
9. Morrone LF, Di Paolo S, Logoluso F, Schena A, Stallone G, Giorgino F, Schena FP. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation 1997; 64: 913-8.
10. Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttranplant erythrocytosis. Kidney Int 2003; 63: 1187-94.
11. Wang AY, Yu AW, Lam CW, Yu LM, Li PF, Goh J, Lui SF. Effects of losartan and enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis. Am J Kidney Dis 2002; 39: 600-8.
12. Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in haemodialysis patients. Am J Nephrol 1984; 4: 355-60.
13. Hirakata H, Onoyama K, Hori K, Fujishima M. Partecipation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic haemodialysis patient. Clin Nephrol 1986; 26: 27-32.
14. Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic haemodialysis patients. J Cardiovasc Pharmacol 1989; 13 (suppl): S27-30.
15. Walter J. Does captopril decrease the effect of human recombinant erythropoietin in haemodialysis patients? Nephrol Dial Transplant 1994; 8: 1428-31.
16. Hesse E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 1996; 11: 749-51.
17. Erturk S, Ates K, Duman N, Karatan O, Erbay B, Ertug E. Unresponsiveness to recombinant human erythropoietin in hemodialysis patients: possible implications of angiotensin converting enzyme inhibitors. Nephrol Dial Transplant 1996; 11: 396-7.
18. Matsumura M, Nomura H, Koni I, Mabuchi H. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin in haemodialysis patients. Nephron 1997; 77: 164-8.
19. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1206-10.
20. Erturk S, Nergizoglu G, Ates K, Duman N, Erbay B, Karatan O, Ertug AE. The impact of withdrawing of ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1912-6.
21. Conlon PJ, Albers F, Butterly D, Schwab SJ. ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients. Nephrol Dial Transplant 1994; 9: 1358.
22. Sanchez JA. ACE inhibitors do not decrease rHuEPO response in patients with end-stage renal failure. Nephrol Dial Transplant 1995; 10: 1476-7.
23. Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic haemodialysis patients: any evidence of erythropoietin resistance? Am J Kidney Dis 1996; 28: 535-40.
24. Charytan C, Goldfarb-Rumyantzev A, Wang YF, Schwenk MH, Spinowitz BS. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients. Am J Nephrol 1998; 18: 498-503.
25. Chew CG, Weise MD, Disney APS. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2047-9.
26. Schiffl H, Lang SM. Angiotensin-converting enzyme inhibitors but not Angiotensin II AT1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease. Nephron 1999; 81: 106-8.
27. Abu-Alfa AK, Cruz DN, Perazella MA, Mahanensmith RL, Simon D, Bia MJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in haemodialysis patients. Am J Kidney Dis 2000; 35: 1076-82.
28. Kamper AL, Nielsen OJ. Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest 1990; 50: 611-8.